A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)

Allergan

Status: Completed

Conditions: Macular Edema; Retinal Vein Occlusion

Treatments: Drug: dexamethasone 700 ug intravitreal implant

Study type: Observational

Funder types: Industry

Identifiers

NCT01571557

MAF/AGN/OPH/RET/011

Details and patient eligibility

About

This study will evaluate the relationship between time since onset of macular oedema symptoms and the achievement of vision gain in patients prescribed OZURDEX®. All care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and local standard of medical care.

Enrollment: 573 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of macular edema following retinal vein occlusion
• Prescribed OZURDEX®

Exclusion criteria

• Previous treatment with OZURDEX®

Trial design

573 participants in 1 patient group

OZURDEX®

Description:

OZURDEX® (dexamethasone 700 ug intravitreal implant) administered according to standard of care.

Treatment:

Drug: dexamethasone 700 ug intravitreal implant